Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers. / Kruuse, C; Iversen, Helle Klingenberg; Jansen-Olesen, I; Edvinsson, L; Olesen, J.
In: Cephalalgia : an international journal of headache, Vol. 30, No. 4, 04.2010, p. 467-74.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers
AU - Kruuse, C
AU - Iversen, Helle Klingenberg
AU - Jansen-Olesen, I
AU - Edvinsson, L
AU - Olesen, J
PY - 2010/4
Y1 - 2010/4
N2 - The role of nitric oxide (NO) in migraine has been studied in the experimental glyceryl trinitrate (GTN)-infusion headache model. We hypothesized that GTN-induced headache may activate the trigeminovascular system and be associated with increased levels of sensory neuropeptides, including calcitonin gene-related peptide (CGRP). CGRP, vasoactive intestinal peptide (VIP), neuropeptide Y (NPY) and somatostatin plasma levels were measured before and after placebo/sumatriptan injection and during GTN-induced headache. Following a double-blind randomized cross-over design, 10 healthy volunteers received subcutaneous sumatriptan 6 mg or placebo. This was succeeded by 20 min of GTN (0.12 µg kg(-1) min(-1)) infusion. At baseline no subject reported headache (using verbal rating scale from 0 to 10) and the jugular CGRP-like immunoreactivity (-LI) level was 18.6 ± 2.5 pmol/l. After a 20-min intravenous infusion of GTN 0.12 µg kg(-1) min(-1), median peak headache intensity was 4 (range 2-6) (P < 0.05), while jugular CGRP-LI levels were unchanged (19.0 ± 2.8 pmol/l; P > 0.05). There were no changes in VIP-, NPY- or somatostatin-LI. In conclusion, the NO donor GTN appears not to induce headache via immediate CGRP release.
AB - The role of nitric oxide (NO) in migraine has been studied in the experimental glyceryl trinitrate (GTN)-infusion headache model. We hypothesized that GTN-induced headache may activate the trigeminovascular system and be associated with increased levels of sensory neuropeptides, including calcitonin gene-related peptide (CGRP). CGRP, vasoactive intestinal peptide (VIP), neuropeptide Y (NPY) and somatostatin plasma levels were measured before and after placebo/sumatriptan injection and during GTN-induced headache. Following a double-blind randomized cross-over design, 10 healthy volunteers received subcutaneous sumatriptan 6 mg or placebo. This was succeeded by 20 min of GTN (0.12 µg kg(-1) min(-1)) infusion. At baseline no subject reported headache (using verbal rating scale from 0 to 10) and the jugular CGRP-like immunoreactivity (-LI) level was 18.6 ± 2.5 pmol/l. After a 20-min intravenous infusion of GTN 0.12 µg kg(-1) min(-1), median peak headache intensity was 4 (range 2-6) (P < 0.05), while jugular CGRP-LI levels were unchanged (19.0 ± 2.8 pmol/l; P > 0.05). There were no changes in VIP-, NPY- or somatostatin-LI. In conclusion, the NO donor GTN appears not to induce headache via immediate CGRP release.
KW - Adult
KW - Calcitonin Gene-Related Peptide
KW - Cross-Over Studies
KW - Female
KW - Headache
KW - Humans
KW - Male
KW - Neuropeptide Y
KW - Nitric Oxide
KW - Nitric Oxide Donors
KW - Nitroglycerin
KW - Reference Values
KW - Somatostatin
KW - Sumatriptan
KW - Vasoactive Intestinal Peptide
KW - Vasoconstrictor Agents
U2 - 10.1111/j.1468-2982.2009.01963.x
DO - 10.1111/j.1468-2982.2009.01963.x
M3 - Journal article
C2 - 19673898
VL - 30
SP - 467
EP - 474
JO - Cephalalgia
JF - Cephalalgia
SN - 0800-1952
IS - 4
ER -
ID: 128983016